Viracta Therapeutics (VIRX) Projected to Post Quarterly Earnings on Thursday

Viracta Therapeutics (NASDAQ:VIRX) will likely be posting its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Viracta Therapeutics to post earnings of ($0.13) per share for the quarter.

Viracta Therapeutics Stock Down 1.3 %

VIRX stock opened at $0.02 on Tuesday. The firm has a 50 day moving average of $0.12 and a 200 day moving average of $0.18. The stock has a market capitalization of $894,240.00, a PE ratio of -0.02 and a beta of 0.70. Viracta Therapeutics has a 52 week low of $0.01 and a 52 week high of $1.31.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Royal Bank of Canada lowered their target price on shares of Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. Rodman & Renshaw reiterated a “neutral” rating and issued a $0.25 target price (down from $3.50) on shares of Viracta Therapeutics in a research note on Friday, December 27th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Viracta Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $4.05.

About Viracta Therapeutics

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.